EGFRvIII escapes down-regulation due to impaired internalization and sorting to lysosomes

Carcinogenesis

Volumn 28, Issue 7, 2007, Pages 1408-1417

  Grandal, Michael V ^a   Zandi, Roza ^b   Pedersen, Mikkel W ^b   Willumsen, Berthe M ^c   van Deurs, Bo ^b   Poulsen, Hans S ^b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b Mental Health Services CPH   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CBL PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 8; GROWTH FACTOR RECEPTOR BOUND PROTEIN 2; MUTANT PROTEIN; TYROSINE; UBIQUITIN PROTEIN LIGASE; UNCLASSIFIED DRUG;

ARTICLE; CELL SELECTION; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; INTERNALIZATION; LYSOSOME; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; PROTEIN TRANSPORT; UBIQUITINATION;

CELL LINE, TUMOR; CELL MEMBRANE; DOWN-REGULATION; ENDOCYTOSIS; EPIDERMAL GROWTH FACTOR; GRB2 ADAPTOR PROTEIN; HUMANS; LYSOSOMES; PHOSPHORYLATION; PROTEIN TRANSPORT; PROTO-ONCOGENE PROTEINS C-CBL; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; UBIQUITINS;

EID: 34547730932     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgm058     Document Type: Article

References (56)

1. Moscatello,D.K. et al. (1995) Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Res., 55, 5536-5539.
2. Olapade-Olaopa,E.O. et al. (2000) Evidence for the differential expression of a variant EGF receptor protein in human prostate cancer. Br. J. Cancer, 82, 186-194.
3. Wikstrand,C.J. et al. (1998) The class III variant of the epidermal growth factor receptor (EGFRvIII): Characterization and utilization as an immunotherapeutic target. J. Neurovirol., 4 148-158.
4. Okamoto,L. et al. (2003) Expression of constitutively activated EGFRvIII in non-small cell lung cancer. Cancer Sci., 94, 50-56.
5. Bantra,S. et al.,(1995) Epidermal growth factor ligand-independent, unregulated, cell-transforming potential of a naturally occurring human mutant EGFRAvIII gene. Cell Growth Diff. 6, 1251-1259.
6. Podersen,M.W. et al. (2004) Expression of a naturally occurring constitutively active variant of the epidermal growth factor receptor in mouse fibroblasts increases motility. Int. J. Cancer, 108, 643-653.
7. Pedersen,M.W. et al. (2005) Analysis of the epidermal growth factor receptor specific transcriptome: Effect of receptor expression level and an activating mutation. J. Cell. Biochem., 96, 412-427.
8. Pedersen,M.W. et al. (2005) Differential response to gefitinib of cells expressing normal BGFR and the mutant EGFRvIII. Br. J. Cancer 93, 915-923.
9. Burgess,A.W. et al. (2003) An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Mol. Cell, 12, 541-552.
10. Kuan,C.T. et al. (2001) EGF mutant receptor vIII as a molecular target in cancer therapy. Endocr relat. cancer, 8, 83-96.
11. Sugawa,N. et al. (1990) Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas. PNAS, 87, 8602-8606.
12. Ekstrand,A.J. et al. (1994) Functional characterization of an EGF receptor with a truncated extracellular domain expressed in glioblastomas with EGFR gene amplification. Oncogene, 9, 2313-2320.
13. Huang,F. et al. (2005) Growth factor receptor binding protein 2-mediated recruitment of the RING domain of Cb1 to the epidermal growth factor receptor is essential and sufficient to support receptor endocytosis. Mol. Biol. Cell, 16, 1268-1281.
14. Damstrup,L. et al. (2002) Epidermal growth factor receptor mutation type III transfected into a small cell lung cancer cell line is predominantly localized at the cell surface and enhances the malignant phenotype. Int. J. Cancer, 97, 7-14.
15. Wikstrand,C.J. et al. (1997) Cell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor, EGFR-vIII. Cancer Res., 57, 4130-4140.
16. Fernandes,H. et al. (2001) Glycosylation-induced conformational modification positively regulates receptor-receptor association. A study with an aberrant epidermal growth factor receptor (EGFRvIII/Delta EGFR) expressed in cancer cells. J. Biol. Chem., 276, 5375-5383.
17. Luwor, R.B. et al. (2004) The tumor-specific de2-7 epidermal growth factor receptor (EGFR) promotes cells survival and heterodimenzes with the wild-type EGFR. Oncogene, 23, 6095-6104.
18. Montgomery,R.B. (2002) Antagonistic and agonistic effects of quinazoline tyrosine kinase inhibitors on mutant EGF receptor function. Int. J. Cancer, 101, 111-117.
19. O'Rourke,D.M. et al. (1998) Inhibition of a naturally occurring EGFR oncoprotein by the p185neu ectodomain: Implications for subdomain contributions to receptor assembly. Oncogene, 16, 1197-1207.
20. Tang,C.K. et al. (2000) Epidermal growth factor receptor vIII enhances tumorigenicity in human breast cancer. Cancer Res., 60 3081-3087.
21. Grovdal,L.M. et al. (2004) Direct interaction of Cb1 with pTyr 1045 of the EGF receptor (EGFR) is required to sort the EGFR to lysosomes for degradation. Exp. Cell Res., 300, 388-395.
22. Jiang,X. et al. (2003) Epidermal growth factor receptor internalization through clathrin-coated pits requires Cb1 RING finger and proline-rich domains but not receptor polyubiquitylation. Traffic 4, 529-543.
23. Jiang,X. et al. (2003) Grb2 regulates internalization of EGF receptors through clathrin-coated pits. Mol. Biol. Cell, 14, 858-870.
24. Levkowitz,G. et al. (1998) c-Cb1/Sli-1 regulates endocytic sorting and ubiquitination of the epidermal growth factor receptor. Genes Dev., 12, 3663-3674.
25. Levkowitz,G. et al. (1999) Ubiquitin ligase activity and tyrosine phosphorylation underlie suppression of growth factor signaling by c-Cb1/ Sli-1. Mol. Cell, 4, 1029-1040.
26. Longva,K.E. et al. (2002) Ubiquitination and proteasomal activity is required for transport of the EGF receptor to inner membranes of multi-vesicular bodies. J. Cell Biol., 156, 843-854.
27. Stang,E. et al. (2004) Cb1-dependent ubiquitination is required for progression of EGF receptors into clathrin-coated pits. Mol. Biol. Cell, 15, 3591-3604.
28. Waterman,H. et al. (2002) A mutant EGF-receptor defective in ubiquitylation and endocytosis unveils a role for Grb2 in negative signaling. EMBO J., 21, 303-313.
29. Wiley,H.S. et al. (1991) The role of tyrosine kinase activity in endocytosis, compartmentation, and down-regulation of the epidermal growth factor receptor. J. Biol. Chem., 266, 11083-11094.
30. Davies,G.C. et al. (2006) EGFRvIII undergoes activation-dependent down-regulation mediated by the Cb1 proteins. Oncogene, 25, 6497-6509.
31. Han,W. et al. (2006) Hypophosphorylation of residue Y1045 leads to defective downregulation of EGFRvIII. Cancer Biol. Ther., 5, 1361-1368.
32. Haslekas,C. et al. (2005) The inhibitory effect of ErbB2 on epidermal growth factor-induced formation of clathrin-coated pits correlates with retention of epidermal growth factor receptor-ErbB2 oligomeric complexes at the plasma membrane. Mol. Biol. Cell, 16, 5832-5842.
33. Abulrob,A. et al. (2004) Interactions of EGFR and caveolin-1 in human glioblastoma cells: Evidence that tyrosine phosphorylation regulates EGFR association with caveolae. Oncogene, 23, 6967-6979.
34. Delft,S.V. et al. (1997) Association and colocalization of Eps15 with adaptor protein-2 and clathrin. J. Cell Biol., 136, 811-821.
35. Confalonieri,S. et al. (2000) Tyrosine phosphorylation of Eps15 is required for ligand-regulated, but not constitutive, endocytosis. J. Cell Biol., 150, 905-912.
36. Sorkina,T. et al. (1999) Clathrin, adaptors and eps15 in endosomes containing activated epidermal growth factor receptors. J. Cell Sci. 112, 317-327.
37. Huang,F. et al. (2004) Analysis of clathrin-mediated endocytosis of epidermal growth factor receptor by RNA interference. J. Biol. - Chem., 279, 16657-16661.
38. Basu,S.K. et al. (1981) Monensin interrupts the recycling of low density lipoprotein receptors in human fibroblasts. Cell, 24 493-502.
39. Stein,B.S. et al. (1984) Complete inhibition of transferrin recycling by monensin in K562 cells. J. Biol. Chem., 259, 14762-14772.
40. Drose,S. et al. (1997) Bafilomycins and concanamycins as inhibitors of V-ATPases and P-ATPases. J. Exp. Biol., 200, 1-8.
41. van Deurs,B. et al. (1996) Inhibition of the vacuolar H(+)-ATPase with bafilomycin reduces delivery of internalized molecules from mature multi-vesicular endosomes to lysosomes in HEp-2 cells. Eur J. Cell Biol., 69, 343-350.
42. Huet,C. et al. (1980) The antibody-induced clustering and endocytosis of HLA antigens on cultured human fibroblasts. Cell, 21, 429-438.
43. Schreiber,A.B. et al. (1983) Biological role of epidermal growth factor-receptor clustering. Investigation with monoclonal anti-receptor antibodies. J. Biol. Chem., 258, 846-853.
44. Schwartz,A.L. et al. (1986) Antibody-induced receptor loss. Different fates for asialoglycoproteins and the asialoglycoprotein receptor in HepG2 cells. J. Biol. Chem., 261, 15225-15232.
45. Winkler,M.E. et al. (1989) Epidermal growth factor and transforming growth factor alpha bind differently to the epidermal growth factor receptor. Biochemistry, 28, 6373-6378.
46. Hommelgaard,A.M. et al. (2004) Association with membrane protrusions makes ErbB2 an internalization-resistant receptor. Mol. Biol. Cell, 15, 1557-1567.
47. Maxfield,F.R. et al. (2004) Endocytic recycling. Nat. Rev. Mol. Cell Biol., 5, 121-132.
48. Huang,H.-J.S. et al. (1997) The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by treshold levels of constitutive tyrosine phosphorylation and unattenuated signaling. J. Biol. Chem., 272, 2927-2935.
49. Moscatello,D.K. et al. (1996) Transformational and altered signal transduction by a naturally occurring mutant EGF receptor. Oncogene 13, 85-96.
50. Prigent,S.A. et al. (1996) Enhanced tumorigenic behavior of glioblastoma cells expressing a truncated epidermal growth factor receptor is mediated through the Ras-Shc-Grb2 pathway. J. Biol. Chem. 271, 25639-25645.
51. Ravid,T. et al. (2004) c-Cb1-mediated ubiquitinylation is required for epidermal growth factor receptor exit from the early endosomes. J. Biol. Chem., 279, 37153-37162.
52. de Melker,A.A. et al. (2004) Ubiquitin ligase activity of c-Cb1 guides the epidermal growth factor receptor into clathrin-coated pits by two distinct modes of Eps15 recruitment. J. Biol. Chem., 279 55465-55473.
53. Schmidt,M.H. et al. (2003) Epidermal growth factor receptor signaling intensity determines intracellular protein interactions, ubiquitination, and internalization. Proc. Natl Acad. Sci. USA, 100, 6505-6510.
54. Baulida,J. et al. (1996) All ErbB receptors other than the epidermal growth factor receptor are endocytosis impaired. J. Biol. Chem., 271, 5251-5257.
55. Lerdrup,M. et al. (2006) Geldanamycin stimulates internalization of ErbB2 in a proteasome-dependent way. J. Cell Sci., 119, 85-95.
56. Sorkin,A. et al. (1993) The carboxyl terminus of epidermal growth factor receptor/erbB-2 chimerae is internalization impaired. Oncogene 8, 3021-3028.